Anti-platelet Therapy in the Primary Prevention of Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease

Trial Profile

Anti-platelet Therapy in the Primary Prevention of Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Ticagrelor (Primary) ; Aspirin
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacodynamics
  • Acronyms APPLE-COPD:ICON 2
  • Most Recent Events

    • 01 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 09 Dec 2015 Accrual to date is 2% according to United Kingdom Clinical Research Network record.
    • 10 Nov 2015 Accrual to date is 0% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top